{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:21:16Z","timestamp":1789770076055,"version":"4.0.1"},"reference-count":43,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Autologous Chimeric antigen receptor (CAR) T-cell therapies have demonstrated substantial efficacy in patients with relapsed or refractory hematologic malignancies; however, their implementation has been constrained by regulatory barriers. Risk Evaluation and Mitigation Strategies (REMS), mandated by the U.S. Food and Drug Administration (FDA), were initially implemented to mitigate risks associated with cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and other treatment-related toxicities. On 27 June 2025, the FDA removed REMS requirements for all approved B-cell maturation antigen (BCMA) and CD19-directed autologous CAR T-cell therapies, citing that current product labeling sufficiently communicates safety information. Key regulatory changes include the elimination of site certification and tocilizumab stocking requirements, a reduction in the recommended post-infusion proximity period from four weeks to two weeks, increased flexibility regarding monitoring locations, and a shortened driving restriction from eight weeks to two weeks. This review examines the rationale for the REMS requirements for CAR T-cell therapies, synthesizes contemporary safety data from clinical trials and real-world practice, and explores the implications of this regulatory shift for access to care, particularly in rural and underserved populations. The removal of REMS requirements may facilitate broader implementation of CAR T-cell therapies and alleviate logistical and institutional barriers, offering the potential to expand access while preserving patient safety.<\/jats:p>","DOI":"10.3390\/cancers17193216","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:38:08Z","timestamp":1759397888000},"page":"3216","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2168-9275","authenticated-orcid":false,"given":"Angel Luis","family":"Orosco-Ttamina","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, MedStar Health Georgetown University, Baltimore, MD 21218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Arana Yi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazie","family":"Tsang","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","unstructured":"U.S. Food and Drug Administration (2025, September 29). What\u2019s in a REMS? U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/risk-evaluation-and-mitigation-strategies-rems\/whats-rems."},{"key":"ref_2","unstructured":"U.S. Food and Drug Administration (2025, August 10). FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T-Cell Immunotherapies, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor."},{"key":"ref_3","unstructured":"KYMRIAH (Tisagenlecleucel) Prescribing Information (2025, August 09). East Hanover (NJ): Novartis Pharmaceuticals Corporation, Available online: https:\/\/www.fda.gov\/media\/107296\/download."},{"key":"ref_4","unstructured":"YESCARTA (Axicabtagene Ciloleucel) Prescribing Information (2025, August 09). Santa Monica (CA): Kite Pharma, Inc, Available online: https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"ref_5","unstructured":"TECARTUS (Brexucabtagene Autoleucel) Prescribing Information (2025, August 09). Santa Monica (CA): Kite Pharma, Inc, Available online: https:\/\/www.fda.gov\/media\/140409\/download."},{"key":"ref_6","unstructured":"BREYANZI (Lisocabtagene Maraleucel) Prescribing Information (2025, August 09). Summit (NJ): Bristol-Myers Squibb, Available online: https:\/\/www.fda.gov\/media\/187950\/download."},{"key":"ref_7","unstructured":"ABECMA (Idecabtagene Vicleucel) Prescribing Information (2025, August 09). Summit (NJ): Bristol-Myers Squibb, Available online: https:\/\/www.fda.gov\/media\/147055\/download."},{"key":"ref_8","unstructured":"CARVYKTI (Ciltacabtagene Autoleucel) Prescribing Information (2025, August 09). Horsham (PA): Janssen Biotech, Inc, Available online: https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/10428194.2022.2030475","article-title":"Incidence of thrombosis in relapsed\/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience","volume":"63","author":"Melody","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-Analysis of 5,517 Lymphoma and Myeloma Patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_18","unstructured":"American Society of Hematology (2025, August 10). FDA-Mandated CAR-T Monitoring Period Could Be Halved. Available online: https:\/\/www.hematology.org\/newsroom\/press-releases\/2024\/fda-mandated-car-t-monitoring-period-could-be-halved."},{"key":"ref_19","first-page":"16","article-title":"CAR T-Cell Therapy Remains Underutilized, Despite Improvements in Access","volume":"13","author":"Berberabe","year":"2024","journal-title":"Targeted Ther. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ccell.2023.10.002","article-title":"Bringing CAR T Cell Therapy Trials to Underserved Populations","volume":"41","author":"Badr","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-024-00747-6","article-title":"Disparities in clinical trial enrollment- focus on CAR-T and bispecific antibody therapies","volume":"20","author":"Islam","year":"2025","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_23","unstructured":"U.S. Congress (2025, September 04). Diverse and Equitable Participation in Clinical Trials (DEPICT) Act of 2022, H.R.6584, 117th Congress, Available online: https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/6584."},{"key":"ref_24","unstructured":"U.S. Congress (2025, September 04). NIH Clinical Trial Diversity Act of 2023, H.R.3503 \/ S.1701, 118th Congress, Available online: https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/1701."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic Differences among Patients Treated with Chimeric Antigen Receptor T-Cell Therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed\/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transpl. Cell. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/bloodadvances.2023011996","article-title":"Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell NHL Treated with CAR-T Therapy","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jrh.12792","article-title":"Urban-rural differences in cancer mortality: Operationalizing rurality","volume":"40","author":"Davis","year":"2024","journal-title":"J. Rural. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.clml.2024.09.010","article-title":"Sociodemographic Factors Influencing Access to Chimeric Antigen Receptor T-Cell Therapy for Patients with Non-Hodgkin Lymphoma","volume":"25","author":"Khare","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.37765\/ajmc.2021.88737","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am. J. Manag. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T-cell therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients- a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41409-025-02541-1","article-title":"Chimeric antigen receptor T cell therapy in octogenarians with B-cell lymphoma: A real-world US multicenter collaborative study","volume":"60","author":"Mohty","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","article-title":"CAR T-Cell Therapy in the Older Person: Indications and Risks","volume":"24","author":"Shouse","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1007\/s00277-025-06511-x","article-title":"Prophylactic Tocilizumab Prior to Infusion of CD19 CAR T-Cells Reduces Therapy-Related Complications in Older Lymphoma Patients","volume":"104","author":"Stolz","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_38","unstructured":"Association of Community Cancer Centers (2025, August 10). Bringing CAR T-Cell Therapies to Community Oncology. Available online: https:\/\/www.accc-cancer.org\/home\/learn\/precision-medicine\/treatment\/immunotherapy\/car-t-cell-therapy\/bringing-car-t-cell-therapies-to-community-oncology."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamaoncol.2025.0042","article-title":"Key Challenges in CAR T-Cell Therapy Access in Community Oncology","volume":"11","author":"Byrne","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11524-023-00721-2","article-title":"Telehealth as a Tool to Improve Access and Reduce No-Show Rates in a Large Safety-Net Population in the USA","volume":"100","author":"Sumarsono","year":"2023","journal-title":"J. Urban Health"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.amepre.2024.02.012","article-title":"Telemedicine Reduces Missed Appointments but Disparities Persist","volume":"67","author":"Ojinnaka","year":"2024","journal-title":"Am. J. Prev. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2021-149103","article-title":"Pilot implementation of remote patient monitoring program for outpatient management of CAR-T cell therapy","volume":"138","author":"Paludo","year":"2021","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.20.01623","article-title":"Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies","volume":"39","author":"Devine","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3216\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:46:09Z","timestamp":1759398369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":43,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193216"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193216","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}